David Yeung
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
A/Prof David Yeung BSc (Med) MBBS (Hons) UNSW, PhD (Adelaide), FRACP, FRCPA.
TITLEHOLDER.
David Yeung is a postdoctoral research fellow with the Cancer Theme at the SHAMRI. He also has positions with the Royal Adelaide Hospital and SA Pathology as a practicing haematologist and haemato-pathologist, and has affiliations with both the University of Adelaide and the University of South Australia. He had training in clinical and laboratory haematology in Sydney before completing his PhD in Adelaide. His focus is on improving outcomes for patients with chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL). Along with Prof Tim Hughes, David leads several national CML clinical trials, with the aim of optimising the use to tyrosine kinase inhibitors leading to improved efficacy and reduced toxicity. Innovative correlative study research projects attached to this clinical trials allow further understand of the biology underlying resistant cases. David also has project with Prof Deb White of the Cancer Theme, who heads the national effort in understanding and improving outcomes in high risk ALL.
Enquiries are welcome from students potentially interested in research projects regarding CML and ALL.
-
Appointments
Date Position Institution name 2021 - ongoing Clinical Assoc Professor University of Adelaide -
Research Interests
-
Journals
-
Book Chapters
Year Citation 2016 Yeung, D., & Branford, S. (2016). Optimal monitoring of CML treatment: Molecular and mutation analysis. In M. Kizaki (Ed.), Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia (pp. 101-129). Japan: Springer.
2016 Yeung, D., & Hughes, T. (2016). Chronic Myeloid Leukaemia. In A. V. Hoffbrand, & D. R. Higgs (Eds.), Postgraduate Haematology: Seventh Edition (pp. 419-437). Wiley.
Scopus1 -
Conference Papers
Year Citation 2023 White, D. L., Rehn, J. A., Schutz, C. E., Heatley, S. L., Eadie, L. N., Thomson, A., . . . Greenwood, M. (2023). Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies. In BLOOD Vol. 142 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Branford, S., Wadham, C., Shanmuganathan, N., Fernandes, A., Shahrin, N. H., Feng, J., . . . Hughes, T. P. (2023). Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML. In BLOOD Vol. 142 (pp. 5 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Hong, L. E., Kok, C. H., Kutyna, M., Li, J. J., Chhetri, R., Ross, D. M., . . . Hiwase, D. (2023). High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Kamel, M. M., Kutyna, M., Ross, D. M., Lane, S. W., Thompson-Peach, C., Fong, C. Y., . . . Thomas, D. (2023). Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Hiwase, D., Baranwal, A., Shah, S., Kutyna, M., Hahn, C. N., Abdelmajid, M., . . . Shah, M. V. (2023). Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Hiwase, D., Ross, D. M., Lane, S. W., Thompson-Peach, C., Fong, C. Y., Yong, A. S. M., . . . Thomas, D. (2023). Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Kutyna, M., Kamel, M. M., Ross, D. M., Yong, A. S. M., Fong, C. Y., Thompson-Peach, C., . . . Thomas, D. (2023). Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Yeung, D. T., Shanmuganathan, N., Reynolds, J., Branford, S., Walia, M., Yong, A. S. M., . . . Hughes, T. P. (2023). Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study. In BLOOD Vol. 142 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Eadie, L. N., Schutz, C. E., Page, E. C., Conlin, T. S., Heatley, S. L., Lagonik, E., . . . White, D. L. (2023). Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Shah, M. V., Kutyna, M., Shah, S., Tran, E. N. H., Baranwal, A., Ladon, D., . . . Hiwase, D. (2023). Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations Using an Independent International Cohort. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2023 Thompson, J. F., Yeung, D. T., Grose, R. H., & White, D. L. (2023). Synergy of Ruxolitinib and Carfilzomib in Targeting the PAX5::JAK2 fusion I n Vitro: Potential Therapeutic Advantage for a Subset of Ph-like Acute Lymphoblastic Leukemia. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
2022 Poudel, G., Yeung, D. T., White, D. L., Hughes, T., & Pagani, I. S. (2022). <i>PTPN11</i> Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph plus ALL Cells, but Are Sensitive to the Combination. In BLOOD Vol. 140 (pp. 3128-3129). LA, New Orleans: AMER SOC HEMATOLOGY.
2020 Shanmuganathan, N., Wadham, C., Shahrin, N. H., Thomson, D., Feng, J., Saunders, V. A., . . . Branford, S. (2020). Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes. In BLOOD Vol. 136 (pp. 4 pages). AMER SOC HEMATOLOGY.
WoS42018 Yeung, D. T., Grigg, A. P., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2018). Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. In BLOOD Vol. 132 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
WoS52018 Leow, B. C., Eadie, L., Pagani, I. S., Yeung, D. T., Hughes, T. P., & White, D. L. (2018). Clonal Selection Determines Resultant Dominance of Tyrosine Kinase Inhibitor-Resistant Cells in Chronic Myeloid Leukaemia. In HemaSphere Vol. 2 (pp. 503). Stockholm, Sweden: Lippincott, Williams & Wilkins.
2017 Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A. K., Filshie, R. J., . . . Hughes, T. P. (2017). Long-term Follow-up of the ALLG CML8 TWISTER Study of Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML).. In Blood Vol. 130 (pp. 1597). Atlanta: American Society of Hematology. 2016 Marum, J. E., Wang, P. P. S., Stangl, D., Yeung, D. T., Mueller, M. C., Dietz, C. T., . . . Branford, S. (2016). Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
WoS22015 Yeung, D. T., Parker, W. T., Phillis, S., Georgievski, J., Scott, H. S., Hughes, T. P., & Branford, S. (2015). BCR-ABL Assay Sensitivity of MR4.5 Achieved in >90%, and MR5 in >75% of Samples, through mRNA Selection before qRT-PCR. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Singhal, D., Hague, S., Roxby, D., Wee, L. A., Lee, O. -L., Sinha, R., . . . Hiwase, D. K. (2015). RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Marum, J. E., Purins, L., Yeung, D. T., Parker, W. T., Price, D. J., Wang, P. P. S., . . . Branford, S. (2015). Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
2015 Kok, C. H., Leclercq, T. M., Watkins, D., Yeung, D. T., Saunders, V. A., White, D. L., & Hughes, T. P. (2015). A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. 2015 Hughes, T. P., Cervantes, F., Leber, B., Spector, N., Lipton, J. H., Pasquini, R., . . . Branford, S. (2015). ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL). In HAEMATOLOGICA Vol. 100 (pp. 61-62). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION. 2013 White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of In Vivo Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. In Blood Vol. 122 (pp. 256). American Society of Hematology.
2011 Branford, S., Yeung, D. T., Prime, J., Ross, D., & Hughes, T. P. (2011). Imatinib Dose Interruption in Responding CML Patients Is Associated with Characteristic BCR-ABL Kinetics, Which Could Help to Differentiate Non-Adherence From Drug Resistance. In BLOOD Vol. 118 (pp. 55). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 White, D. L., Saunders, V. A., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . . Hughes, T. P. (2011). The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients. In BLOOD Vol. 118 (pp. 735). San Diego, CA: AMER SOC HEMATOLOGY. 2011 Hughes, T. P., Lipton, J. H., Leber, B., Spector, N., Cervantes, F., Pasquini, R., . . . Branford, S. (2011). Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR, After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. In BLOOD Vol. 118 (pp. 278). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12011 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. In BLOOD Vol. 118 (pp. 208). San Diego, CA: AMER SOC HEMATOLOGY.
WoS12010 White, D. L., Saunders, V., Frede, A., GrootObbink, K., Slader, C., Yeung, D. T., . . . Hughes, T. (2010). Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study. In BLOOD Vol. 116 (pp. 160-161). Orlando, FL: AMER SOC HEMATOLOGY. 2010 White, D. L., Saunders, V., Andrew, M., Rofe, A., Slader, C., Yeung, D. T., . . . Hughes, T. (2010). Imatinib PK: Observations From the TIDEL II Study.. In BLOOD Vol. 116 (pp. 943). Orlando, FL: AMER SOC HEMATOLOGY. 2010 Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. In Proceedings of 2010 American Society of Hematology conference (pp. 1-2). Florida. 2010 Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. In BLOOD Vol. 116 (pp. 96). Orlando, FL: AMER SOC HEMATOLOGY.
WoS10 -
Conference Items
Year Citation 2021 Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 4th International T-ALL/T-NHL conference: T-ALL2020: Omics, genetics and therapy. 2021 Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS). 2020 Poudel, G., Yeung, D., White, D., Hughes, T., & Pagani, I. (2020). Understanding the mechanisms of imatinib resistance in a Ph+ acute lymphoblastic leukaemia cell line. Poster session presented at the meeting of The 59th ASMR National Scientific Conference. 2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). The MYB-TYK2 gene fusion induces B-cell acute lymphoblastic leukaemia in in vitro and in vivo models and can be effectively targeted by the dual SYK/JAK inhibitor, cerdulatinib. Poster session presented at the meeting of 25th Congress of The European Hematology Association. Frankfurt, Germany (virtual meeting). 2020 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Targeted pseudo-alignment technique for rapid and accurate identification of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of 14th Annual Florey Postgraduate Conference. Adelaide, South Australia. 2020 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Pseudo-alignment technique for accurate detection of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) 2020 National Conference. Canberra, ACT. 2020 Tavakoli, P. S., Eadie, L. N., Heatley, S. L., Yeung, D. T., & White, D. L. (2020). Vorinostat treatment demonstrated efficacy against MYB-TYK2 altered B-cell acute lymphoblastic leukaemia in in vitro and in vivo models. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. 2020 Eadie, L. N., Rehn, J., Heatley, S. L., McClure, B. J., Schutz, C. S., Breen, J., . . . White, D. L. (2020). Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: AMER SOC HEMATOLOGY.
WoS12020 Eadie, L., Heatley, S., McClure, B., Schutz, C., Breen, J., Hughes, T., . . . White, D. (2020). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group. 2020 McClure, B., Heatley, S., Grose, R., Yeung, D., & White, D. (2020). Activation of the immune cell repertoire in B-cell acute lymphoblastic leukaemia.. Poster session presented at the meeting of Australian & New Zealand Children’s Haematology/Oncology Group. 2020 Downes, C. E. J., McClure, B. J., Rehn, J., Breen, J., Bruning, J. B., Yeung, D. T., & White, D. L. (2020). Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an <i>in Vitro</i> model of a High-Risk Acute Lymphoblastic Leukemia. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: AMER SOC HEMATOLOGY.
WoS12019 Page, E. C., Heatley, S. L., Yeung, D. T., Thomas, P. Q., & White, D. L. (2019). A Novel Role for <i>HMGN1</i> in Down Syndrome Acute Lymphoblastic Leukemia. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
2019 Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of 1st European Society of Haematology (ESH) Translational Conference on ALL. Berlin, Germany. 2019 Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia. 2019 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L., Schutz, C. E., . . . White, D. L. (2019). Investigating “alignment-free” computational techniques for the accurate identification of Acute Lymphoblastic Leukaemia (ALL) gene fusion events. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia. 2019 Heatley, S. L., McClure, B. J., Eadie, L. N., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia. 2019 Yeung, D., Greenwood, M., Rehn, J., Heatley, S., McClure, B., Eadie, L., . . . White, D. (2019). High risk genomic alterations identified at the time of diagnosis are strongly associated with MRD and subsequent poor outcomes in AYA ALL patients treated on a pediatric inspired chemotherapy regimen. Poster session presented at the meeting of Blood. Orlando, CA: American Society of Hematology.
2018 Shanmuganathan, N., Branford, S., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2018). The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
WoS52018 Asari, K., Leclercq, T., Srihari, S., Fitter, S., Yeung, D., Hughes, T., . . . White, D. L. (2018). in vitro modelling of Ph-like ALL uncovers novel genomic alterations associated with TKI-resistance as a consequence of targeted therapy. Poster session presented at the meeting of Childhood Leukaemia and Lymphoma Symposium. Helsinki, Finland. 2018 Heatley, S. L., Mayne, B. T., McClure, B. J., Kok, C., Sadras, T., Dang, P., . . . White, D. L. (2018). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of 23rd Congress of European Hematology Association. Stockholm, Sweden. 2018 Downes, C. E., McClure, B. J., Heatley, S. L., Yeung, D. T., & White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk B-ALL JAK2-fusion. Poster session presented at the meeting of NDLR. 2018 Heatley, S. L., McClure, B. J., Kok, C., Sadras, T., Dang, P., Galbraith, K., . . . White, D. L. (2018). Exploring the genomic diversity of adult and AYA cases with high-risk B-ALL by mRNA sequencing. Poster session presented at the meeting of NDLR. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of APG Student Awards. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of ruxolitinib resistance mutations in Pro-B cells driven by a high-risk JAK2 fusion in B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of ASMR. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and Characterisation of Ruxolitinib Resistant Mutations in JAK2-rearranged B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of AGTA. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification of mutations that cause ruxolitinib resistance in Pro-B cells driven by a high-risk B-ALL JAK2-fusion.. Poster session presented at the meeting of ANZCHOG. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of SAHMRI Scientific Seminar. 2018 Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. B., Heatley, S. L., Kok, C., . . . White, D. L. (2018). Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia. Poster session presented at the meeting of EMBL Australia Postgraduate Symposium. 2017 McClure, B. J., Heatley, S. L., Kok, C., Sadras, T., An, J., Quek, K., . . . White, D. L. (2017). EP300-ZNF384 is a recurrent fusion gene with distinct gene expression in adolescent/young adult pre-B-ALL patients. Poster session presented at the meeting of ANZCHOG. 2017 Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A., Filshie, R., . . . Hughes, T. P. (2017). Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). Poster session presented at the meeting of 59th ASH Annual Meeting & Exposition. 2017 Hughes, A., Clarson, J., White, D. L., Yeung, D., Hughes, T. P., & Yong, A. S. M. (2017). Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
WoS42017 Yeung, D., Grigg, A., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . . . Hughes, T. P. (2017). Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. 2017 Downes, C. E., McClure, B. M., Heatley, S. H., Sadras, T. S., Hughes, T. H., Kok, C. K., . . . White, D. W. (2017). Identification and cloning of a novel GOLGA4-JAK2 fusion from an adult patient with B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster session presented at the ASMR SA Scientific Meeting. Adelaide. 2017 Heatley, S., Sadras, T., Kok, C., Nievergall, E., Quek, K., Dang, P., . . . White, D. (2017). High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Poster session presented at the meeting of Abstracts of the 57th Annual Meeting of the American Society of Hematology, as published in Blood. Orlando, FL: American Society of Hematology.
WoS22016 Sadras, T., Heatley, S., Dang, P., Kok, C., Quek, K., Nievergall, E., . . . White, D. L. (2016). A nine-gene signature defines 2 groups of CRLF2 rearranged B-ALL patients with distinctive genetic features. Poster session presented at the meeting of .. Athens. 2016 Saunders, V. A., Wang, J., Lu, L., Eadie, L. N., McLean, J. A., Goyne, J. M., . . . Hughes, T. P. (2016). A Low Concentration of ABL001 Potentiates <i>In Vitro</i> TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
WoS12016 Sadras, T., Heatley, S., Kok, C., Quek, K., Dang, P., Nievergall, E., . . . White, D. L. (2016). CRLF2 rearranged B-ALL cases with a Ph-like gene signature are enriched for JAK2 mutations. Poster session presented at the meeting of .. Noosa, QLD. 2016 Kok, C. H., Watkins, D., Wang, J., Saunders, V., Goyne, J., Pagani, I. S., . . . White, D. L. (2016). High Gene Expression of hist1h2ag and hist1h4a Reduces Imatinib Uptake into CML Cells and Predicts Poor Response to Frontline Imatinib Therapy. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2016 Heatley, S., Sadras, T., McClure, B., Kok, C. H., Dang, P., Nievergall, E., . . . White, D. L. (2016). The Incidence of Ph-like Acute Lymphoblastic Leukaemia (ALL) Increases with Age and is Characterised by Poor Outcome. Poster session presented at the meeting of Poster Session. Melbourne, VIC. 2014 Branford, S., Yeung, D., Ross, D., Parker, W., Braley, J., Seymour, J., & Hughes, T. (2014). The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment. Poster session presented at the meeting of Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology. 2014 Yeung, D. T., Vidovic, L., Tang, C., White, D. L., Branford, S., Hughes, T. P., & Yong, A. S. M. (2014). KIR2DL5B Genotype Independently Predicts Poor Outcomes in CML-CP Patients Switched to Nilotinib after Suboptimal Responses to Imatinib and May Refine Prognosis in Patients with EMR Failure. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY. 2014 Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology.
WoS12014 Branford, S., Ross, D., Yeung, D., Braley, J., & Hughes, T. (2014). Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint. Poster session presented at the meeting of Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology.
WoS22014 Parker, W. T., Phillis, S. R., Yeung, D. T., Lawrence, D., Schreiber, A., Wang, P., . . . Branford, S. (2014). Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY.
WoS42013 Parker, W., Yeoman, A., Altamura, H., Roberts, N., Yeung, D., Jamison, B., . . . Branford, S. (2013). Additional BCR-ABL1 Mutations Identified By Sensitive Mass Spectrometry In Chronic Phase CML Patients With T315I Treated With Ponatinib Are Associated With Relatively Inferior Responses and Outcome. Poster session presented at the meeting of Blood. Amer Soc Hematology. 2013 Hiwase, D., Yeung, D., Carne, L., Ross, D., Grigg, A., & Hughes, T. (2013). Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis. Poster session presented at the meeting of Blood. Amer Soc Hematology.
WoS82013 Parker, W., Phillis, S., Yeung, D., Hughes, T., Scott, H., & Branford, S. (2013). PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutations. Poster session presented at the meeting of Oral Sessions from the 55th ASH Annual Meeting and Exhibition, as published in Blood. New Orleans, Louisiana: American Society of Hematology. 2013 White, D., Saunders, V., Eadie, L., David, Y., & Hughes, T. P. (2013). The Depth Of <i>In Vivo</i> Kinase Inhibition Achieved Over The First Month Of Nilotinib Therapy Predicts For Subsequent Molecular Response, and Is Closely Related To Nilotinib Plasma Levels. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY.
WoS12012 White, D. L., Saunders, V., Yeung, D., Grigg, A., & Hughes, T. (2012). Early Molecular Response to Imatinib in CP-CML Patients: The Significance of Early Dose Intensity and OCT-1 Activity in Responders and Efficacy of Dose Escalation and Switch to Nilotinib in Non-Responders.. Poster session presented at the meeting of American Society of Haematology. Atlanta, USA. 2012 Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
WoS82012 Parker, W. T., Yeoman, A. L., Jamison, B. A., Yeung, D. T., Scott, H. S., Hughes, T. P., & Branford, S. (2012). The patient's BCR-ABL1 Kinase Domain Mutation History Is Important for Decisions Regarding Tyrosine Kinase Inhibitor Therapy. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
2012 Branford, S., Ross, D., Prime, J., Field, C., Altamura, H., Yeoman, A., . . . Hughes, T. (2012). Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable <i>BCR</i>-<i>ABL1</i>, a Criterion for Imatinib Discontinuation in Patients with CML. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
WoS6
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Co-Supervisor The burden of cure: Secondary malignancy after allogeneic haematopoietic stem cell transplant Doctor of Philosophy Doctorate Full Time Miss Alia Elizabeth Cibich 2024 Co-Supervisor Clinical Transcriptomic Sequencing Analysis Workflows for Acute Lymphoblastic Leukaemia (ALL): Improving Subtype Characterisation in Complex Fusion Events Doctor of Philosophy Doctorate Full Time Miss Ashlee Jean Thomson 2023 Co-Supervisor Interrogating the DUX4 rearranged subtype of B cell Acute Lymphoblastic Leukaemia Doctor of Philosophy Doctorate Full Time Mr Thomas Oliver McGovern 2023 Co-Supervisor Exploring the impact of the gut microbiota on the clinical scenario in Acute Lymphoblastic Leukaemia patients Doctor of Philosophy Doctorate Full Time Miss Cate Viktorija Cheney 2022 Co-Supervisor Characterisation of a novel fusion, genetic contributors and effectiveness of drug combinations in Ph-like Acute Lymphoblastic Leukaemia and the clinical relevance. Doctor of Philosophy Doctorate Full Time Jane Frances Thompson 2021 Co-Supervisor Investigation of current, innovative treatments and the roles of secondary genomic lesions in BCR-ABL1 positive leukaemias Doctor of Philosophy Doctorate Full Time Mr Elias Lagonik 2019 Co-Supervisor Optimisation of Anti-Infective Medications in Patients with haematological Malignancies or Undergoing Haematopoietic Stem Cell Transplantation Doctor of Philosophy Doctorate Full Time Mr Philip Roland Selby -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2020 - 2023 Co-Supervisor Unravelling Resistance Mechanisms in Philadelphia Positive Leukemias: Targeted Treatment Strategies to Overcome Resistance Doctor of Philosophy Doctorate Full Time Mr Govinda Poudel 2016 - 2019 Co-Supervisor Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors In Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Mr Benjamin Chia Sing Leow
Connect With Me
External Profiles
